Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 11, 2025Frontiers in EndocrinologyOpen Access

Established and emerging use of sodium-glucose cotransporter-2 inhibitors in pediatric population with type 2 diabetes: a case report and literature review

View Full Paper
Ask AI
Bookmark
Share

Authors

VCValeria CastoraniECEleonora ChiarleSSSilvia Savastio

Discussion

Loading...

Member takes

Overview

Case report outlines 14-year-old with poorly controlled type 2 diabetes treated with empagliflozin, highlighting emerging therapy options.

Key Points

  • Empagliflozin use improved blood glucose management in a 14-year-old girl with type 2 diabetes.
  • Emerging data supports the use of SGLT2 inhibitors in pediatric patients, showing promising results.
  • A literature review reveals the growing need for effective treatment options for youth-onset type 2 diabetes.
  • SGLT2 inhibitors offer new therapeutic avenues in managing pediatric type 2 diabetes, unlike other traditional agents.

Cite This Study

Castorani et al. (2025) studied this question.

synapsesocial.com/papers/68d4140c713b0b5dfea626e9https://doi.org/10.3389/fendo.2025.1629488
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus2014 · 353 citations